APPENDIX

1. Crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1-2,3-triazole-4-carboxamide of the formula



characterized by characteristic lines at interplanar spacings (d values) of 10.5 Å, 5.14 Å, 4.84 Å, 4.55 Å, 4.34 Å, 4.07 Å, 3.51 Å, 3.48 Å, 3.25 Å, 3.19 Å, 3.15 Å, 3.07 Å, 2.81 Å, determined by means of an X-ray powder pattern.

2. The crystal modification according to Claim 1, characterized by an X-ray powder pattern having the following characteristic lines at interplanar spacings (d values) of 10.9 Å (weak), 10.5 Å (medium), 6.6 Å (weak), 5.63 Å (weak), 5.25 Å (weak), 5.14 Å (medium), 4.94 Å (weak), 4.84 Å (very strong), 4.55 Å (strong), 4.42 Å (very weak), 4.34 Å (medium), 4.23 Å (very weak), 4.16 Å (weak), 4.07 Å (medium), 4.01 Å (weak), 3.68 Å (very weak), 3.64 Å (very weak), 3.60 (weak), 3.56 Å (weak), 3.51 Å (medium), 3.48 Å (medium), 3.38 Å (very weak), 3.25 Å (strong), 3.19 Å (medium), 3.15 Å (medium), 3.11 Å (weak), 3.07 Å (medium), 2.93 Å (very weak), 2.87 Å (very weak), 2.81 Å (medium), 2.76 Å (weak), 2.73 Å (very weak), 2.68 Å (weak), 2.62 Å (very weak), 2.53 Å (weak), 2.43 Å (weak), 2.40 Å (very weak).

3. The crystal modification according to Claim 1 characterized by the following absorptions in the FT-IR spectrum (KBr pellet - transmission method) 3092 $cm^{-1}$ and 3412 $cm^{-1}$.

4. The crystal modification according to Claim 3, characterized by the following absorptions in the FT-IR spectrum (KBr pellet - transmission method): 3412, 3189, 3092, 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, 799, 781, 723, 688 and 640 $cm^{-1}$.

5. The crystal modification according to Claim 1, characterized by the following absorptions in the FT-Raman spectrum (powder - reflection method 180°): 3093, 2972, 1628, 1614, 1558, 1465, 1446, 1393, 1279, 1245, 1147, 1080, 1061, 1036, 1014, 840, 724, 691, 667, 550, 499, 437 and 368 $cm^{-1}$.

6. The crystal modification according to Claim 1, characterized by an endothermic peak in the range from 230°C to 260°C, the peak temperature being 239-245°C and the endothermic signal being 209 J/g +/- 10 J/g.

7. Crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, characterized in that it is identical to the modification A according to Claim 1, but has defects in the crystal lattice.

8. The crystal modification A' according to Claim 7, characterized by line spacings, smaller compared to modification A, between the pairs of lines at interplanar spacings 3.68 Å and 3.64 Å, 3.51 Å and 3.48 Å, and 3.19 Å and 3.15 Å.

9. The crystal modification according to Claim 1 in essentially pure form.

13. Crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, characterized by bands at 3412 $cm^{-1}$ and 3092 $cm^{-1}$ in the FT-IR spectrum.

14. Crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, characterized by a band at 1080 $cm^{-1}$ in the FT-Raman spectrum.

16. The crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, characterized in that it is identical to the modification A according to Claim 2 but has defects in the crystal lattice.

17. The crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, characterized in that it is identical to the modification A according to Claim 3 but has defects in the crystal lattice.

18. The crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, characterized in that it is identical to the modification A according to Claim 4 but has defects in the crystal lattice.

19. The crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, characterized in that it is identical to the modification A according to Claim 5 but has defects in the crystal lattice.

20. The crystal modification A' of the compound 1-2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, characterized in that it is identical to the modification A according to Claim 6 but has defects in the crystal lattice.

21. The crystal modification according to Claim 7 in essentially pure form.

26. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to Claim 1.

28. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to Claim 7.

30. The crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, characterized in that it is identical to the modification A according to Claim 13 but has defects in the crystal lattice.

31. The crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide, characterized in that it is identical to the modification A according to Claim 14 but has defects in the crystal lattice.